Management’s Bet on Viking Therapeutics: Stock Options Signal Long-Term Confidence

While Viking Therapeutics shares continue to navigate a challenging correction, having shed approximately 15% over the past month, a recent development in executive compensation is drawing investor scrutiny. The stock, currently trading around $31.40 and facing technical pressure, is now in focus due to newly granted equity awards. Does this move indicate that corporate leadership anticipates a near-term recovery?

Against the backdrop of recent share price softness, a transaction involving Chief Commercial Officer Neil William Aubuchon has become notable. Corporate filings reveal that Aubuchon was granted 180,000 stock options with an exercise price set at $31.76.

This sends a clear message to the market: the strike price sits slightly above the Read more...